ProMIS Neurosciences Inc PMN

Buzz on the Bullboards: TSX spotlight – Bombardier, Sonoro, PyroGenesis

[Gbathat]

Yikes, 31% ARIA-E for donanemab  How PMN is still not financed through Ph2 or bought out at this point is beyond me. 

[Jonathon Brown]

Bombardier’s aviation advancements, Sonoro’s acquisition, and PyroGenesis' biofuel contributions highlight the opportunities in the Canada. read article.

[goldtech]

https://www.fiercebiotech.com/biotech/foresite-raises-900m-make-big-bets-one-best-biotech-investment-environments

[goldtech]

Scientists all agree soluble toxic oligomers kill neurons, so targeting only the oligomers should stop the propagation of the very toxic proteins that the medical community agrees is the root cause.

[Alex1726]

Well ok but what does it change to the fact that eleminating the bad proteins is not the right target?

[goldtech]

We’re advocating that what may be more meaningful across all degenerative diseases is the loss of normal proteins rather than the measurable fraction of abnormal proteins,” Espay said. “The net effect

[G1945V]

He did not explain how the soluble (amyloid beta) normal protein gets generated in the brain to maintain brain function and keep neurons communicating with one another. G1945V

[Alex1726]

PMN and most of others working to eleminate misfolded proteins got it all wrong. https://www.uc.edu/news/articles/2022/09/decreased-proteins-not-amyloid-plaques-tied-to-alzheimers.html

[G1945V]

"The main safety concerns of donanemab are brain swelling (edema) and micro-bleeding (hemorrhages), both known as amyloid-related imaging abnormalities, or ARIA. In the clinical trial, among

[G1945V]

https://markets.businessinsider.com/news/stocks/buy-rating-affirmed-for-promis-neurosciences-amid-positive-fda-feedback-and-promising-alzheimer-s-treatment-outlook-1033467319 "with lower risks

[Trek1701]

https://www.forbes.com/sites/joshuacohen/2024/06/11/alzheimers-disease-drug-donanemab-gets-unanimous-backing-from-fda-expert-panel/ 1736 patients enrolled in p3. 25% ARIA. 5% underrepresented

[M101]

I predict donanemab gets unanimous backing from FDA advisory committee earlier today. Because money has spoken. Hurray for money, wish we had some.    

[Gbathat]

Phase 1a results announced? Phase 1b financing? Phase 2a financing?

[Alex1726]

https://www.biopharmadive.com/news/lilly-donanemab-alzheimers-fda-advisory-committee-documents/718194/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue

[goldtech]

This Company has always had management problems and their burn rate is pathetic for a biotech that gives out money like it's never ending. This lame BOD does nothing but drain the treasury.

[G1945V]

We saw 97 cents on Dec 26, 2023. G1945V